Effects of rituximab and dexamethasone on regulatory and proinflammatory B-cell subsets in patients with primary immune thrombocytopenia.

Sif GudbrandsdottirMarie BrimnesTania KøllgaardHans C HasselbalchClaus H Nielsen

Published in: European journal of haematology (2017)

Both treatment regimens normalized the frequencies of cytokine-producing B cells. The additional increase in CD5+ B cells after RTX+DXM is compatible with induction of Bregs.

Keyphrases

diffuse large b cell lymphoma
low dose
high dose
peripheral blood
chronic lymphocytic leukemia